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YoBACKGROUND Adults with congenital heart disease (CHD) have been considered potentially high risk for novel
coronavirus disease-19 (COVID-19) mortality or other complications.
OBJECTIVES This study sought to define the impact of COVID-19 in adults with CHD and to identify risk factors
associated with adverse outcomes.
METHODS Adults (age 18 years or older) with CHD and with confirmed or clinically suspected COVID-19 were included
from CHD centers worldwide. Data collection included anatomic diagnosis and subsequent interventions, comorbidities,
medications, echocardiographic findings, presenting symptoms, course of illness, and outcomes. Predictors of death or
severe infection were determined.
RESULTS From 58 adult CHD centers, the study included 1,044 infected patients (age: 35.1  13.0 years; range 18 to 86
years; 51% women), 87% of whom had laboratory-confirmed coronavirus infection. The cohort included 118 (11%) pa-
tients with single ventricle and/or Fontan physiology, 87 (8%) patients with cyanosis, and 73 (7%) patients with pul-
monary hypertension. There were 24 COVID-related deaths (case/fatality: 2.3%; 95% confidence interval: 1.4% to 3.2%).
Factors associated with death included male sex, diabetes, cyanosis, pulmonary hypertension, renal insufficiency, and
previous hospital admission for heart failure. Worse physiological stage was associated with mortality (p ¼ 0.001),
whereas anatomic complexity or defect group were not.
CONCLUSIONS COVID-19 mortality in adults with CHD is commensurate with the general population. The most
vulnerable patients are those with worse physiological stage, such as cyanosis and pulmonary hypertension, whereas
anatomic complexity does not appear to predict infection severity. (J Am Coll Cardiol 2021;77:1644–55) © 2021 by the
American College of Cardiology Foundation.N 0735-1097/$36.00 https://doi.org/10.1016/j.jacc.2021.02.023
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1645AB BR E V I A T I O N S
AND ACRONYM S
CHD = congenital heart disease
CI = confidence interval
COVID-19 = coronavirus
disease-2019
eGFR = estimated glomerular
filtration rate
ICU = intensive care unit
OR = odds ratio
PAH = pulmonary arterial
hypertension
PCR = polymerase chain
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ital heart disease (CHD), numbering >1.5 million in
the United States (4,5), are recognized as a population
with significant morbidity (6) and as vulnerable to
many types of cardiovascular deterioration and
dysfunction. As such, they have largely been consid-
ered high risk and often adopt a highly restrictive life-
style and employment choices accordingly. Early
publications in CHD reported different risks (7,8)
but suggested worse risk in higher physiological
stages (9).
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FIGURE 1 Global Distribution of Contributing Centers
Points identify the location of the 58 congenital heart centers participating in the study.
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1646severe infection, meaning need for intensive care unit
(ICU) admission, endotracheal intubation, acute res-
piratory distress syndrome, or renal replacement
therapy (secondary outcome).SEE PAGE 1656METHODS
STUDY DESIGN. This was an international, multi-
center, retrospective cohort study. Collaborators from
adult CHD centers globally were recruited via the
Adult Congenital Heart Association, the International
Society for Adult Congenital Heart Disease, the Alli-
ance for Adult Research in Congenital Cardiology, the
Canadian Adult Congenital Heart Network, and by
word of mouth to colleagues worldwide. Study
administration and coordination was done by the
University of California, Los Angeles, whereas Oregon
Health and Science University served as the data
coordinating center. The overall study was approved
by both host institutions, and each participating
center obtained local ethics approval.
ELIGIBILITY CRITERIA. Eligible patients met the
following inclusion criteria for enrollment: knowndiagnosis of CHD, age 18 years or older, and either
positive polymerase chain reaction (PCR) for the
novel coronavirus or positive antibody test following
a clinical illness. Patients with a presumptive diag-
nosis of COVID-19 based upon clinical symptoms and
circumstances were also included, because testing
availability and sensitivity were known to vary by
location and assay and over time. Patients with a
known familial aortopathy were included as were
those with syndromes if a congenital heart defect was
present. We excluded patients with patent foramen
ovale, mitral valve prolapse, hypertrophic cardiomy-
opathy, ventricular noncompaction, congenital
arrhythmia, or those who had undergone
heart transplantation.
DATA COLLECTION. For each patient, comprehen-
sive clinical data were abstracted from existing
medical records by collaborating investigators at each
center. Data included anatomic diagnoses, subse-
quent interventions, general anatomic classification,
and physiological stage based on the 2018 American
College of Cardiology/American Heart Association
joint guidelines on adult CHD (9), a history of major
cardiac and noncardiac comorbidities, medications at































Column heights indicate the percentage of each anatomic and/or physiologic subtype from the total cohort. Classification is based on the
scheme as outlined in the American College of Cardiology/American Heart Association 2018 guidelines for adult congenital heart disease (9).
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1647most recent outpatient visit, and most recent labo-
ratory and echocardiographic findings obtained
before but within 12 months of infection. Echo find-
ings included semi-quantitative valve assessment
(mild to moderate to severe). PCR testing results,
clinical presentation, and laboratory and imaging re-
sults during infection and course of illness were also
recorded, including details of any hospitalization.
Race and ethnicity were requested for patients from
collaborating centers within the United States.
Data were entered online using the Research
Electronic Data Capture data management system,
which enables multiuser data collection. Patients
were given study-specific identifiers. No protected
patient identifiers, including dates, were collected.
Quality control was performed by the data coor-
dinating center. Data were reviewed for internal
consistency. For example, designation of cyanosis
was confirmed by a reported resting oxygen satu-
ration of <90%, and patients with Fontan physi-
ology were ensured to have an anatomic defect
consistent with single ventricle palliation. All in-
consistencies and outliers were flagged, and querieswere sent to local investigators for confirmation or
correction.
We used a hierarchical classification to categorize
patients by their single most complex defect type (13),
such that each patient was included in only 1 defect
category. Patients identified as having Eisenmenger
physiology, with both cyanosis and pulmonary hy-
pertension in the setting of a shunt, were designated
as such, and removed from their respective anatomic
defect category. Patients with a systemic right
ventricle included those with transposed great ar-
teries and an atrial switch operation, or congenitally
corrected transposition (biventricular repairs only).
Contributing site investigators were asked to desig-
nate anatomic severity (simple, moderate, or com-
plex) based on the guideline classification scheme (9),
and designations were reviewed for consistency with
the given congenital defect. Discrepancies were clar-
ified or corrected with site investigators as needed.
Similarly, physiological stage designation was
compared with other collected data, such as New York
Heart Association functional class, arrhythmia his-
tory, end-organ dysfunction, valve disease, and so
TABLE 1 Presenting Symptoms of COVID-19 Infection
Fever 458 (44)




Loss of smell 236 (23)
Headache 149 (14)
Chest pain 130 (12)
Diarrhea 108 (10)
Congestion 107 (10)
Productive cough 65 (6)
None* 60 (6)
Loss of taste 66 (6)
Abdominal pain, nausea, vomiting 57 (5)
Chills 39 (4)
Other/miscellaneous 48 (5)
Values are n (%). *Asymptomatic subjects tested before an elective procedure or
in response to a suspected exposure to the novel coronavirus.
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investigators. In some instances when physiological
stage was not provided by local investigators, who
might not have been familiar with the classification
scheme, physiological stage was imputed based on
other provided data with agreement of 2 investigators
blinded to outcomes.
STATISTICAL ANALYSES. From available data, body
surface area, body mass index, and estimated
glomerular filtration rate (eGFR; based on the Modi-
fication of Diet in Renal Disease equation) were
calculated. Severe viral infections were defined as
those that required ICU admission, endotracheal
intubation for mechanical ventilation, acute respira-
tory distress syndrome, renal replacement therapy,
need for extracorporeal membrane oxygenation, or
death. Other cases were considered mild, including
hospitalizations that did not include 1 of the afore-
mentioned criteria, because some patients had other
indications for admission. Patients with either mod-
erate or severe valve regurgitation or stenosis of any
valve, by recent echocardiography as reported by
local investigators, were identified as having moder-
ate to severe valve dysfunction.
Data analyses were performed using SPSS Statistics
for Windows, version 25 (IBM Corp, Armonk, New
York). Overall rates of the primary outcome (death)
and the secondary outcome (severe infection) were
quantified with 95% confidence intervals (CI). Similar
rates were determined by decade of age, CHD defect
group, and by anatomic and/or physiological classi-
fication scheme. Groups with or without primary and
secondary outcomes were compared using the chi-
square test, Fisher exact test, Student’s t-test, or
Mann-Whitney U test, as appropriate. Odds ratios
(ORs) with 95% CIs were determined using binary
logistic regression to report the strength of associa-
tion between risk factor exposure and mortality.
Because of limited mortality events, multivariable
regression was limited to specific comparisons with
no more than 2 independent predictors, and cate-
gorical variables were collapsed to dichotomous var-
iables to avoid empty cells. Analysis including only
PCR-positive patients was repeated to explore
whether the method of diagnosis affected results.
Statistical significance was defined as p < 0.05.
Because of the exploratory nature of this study, no
corrections were made for multiple tests.
RESULTS
STUDY COHORT. A total of 58 CHD centers contrib-
uted to the study (Figure 1). Of 1,115 submitted pa-
tients, 1,044 met full inclusion and/or exclusioncriteria. Mean age was 35.1  13.0 years (range 18 to 86
years), and 51% were women. Most patients (n ¼ 907;
87%) had a positive PCR test or positive antibodies
detected after a clinical illness. The remainder
(n ¼ 137) were diagnosed based on clinical presenta-
tion alone. Most patients (n ¼ 787; 75%) were fol-
lowed by U.S. centers, with race reported in 784 and
ethnicity in 739.
The cohort included a broad representation of the
spectrum of CHD complexity and comorbidity. The
anatomic and/or physiological classification for the
cohort is shown in Figure 2. Previous atrial arrhythmia
occurred in 259 (25.9%) patients, and previous ven-
tricular arrhythmia in 103 (9.7%) patients. There were
132 (12.6%) patients with implanted pacemakers or
defibrillators, 161 (15.4%) patients with hypertension,
88 (8.4%) with known genetic syndromes, 65 (6.2%)
with diabetes, and 19 (1.8%) patients with cirrhosis. In
addition, 23 women were pregnant at the time of
infection.
Fever, dry cough, and malaise were the most
common presenting symptoms, occurring in approx-
imately one-half of the cohort (Table 1). There were 60
(6%) patients who had no presenting symptoms but
were tested based upon a known incidental exposure
or need for clearance before a procedure. Of the total
cohort, 179 patients (17%) required hospitalization,
which included those who tested positive during
admission for other indications. Serum troponin was
reported in 30 patients, all but 1 of whom were hos-
pitalized and was elevated in 22 patients.
PRIMARY OUTCOME: FATALITIES. Death occurred in
28 subjects, of whom 4 were deemed unrelated to
acute COVID-19 infection. One patient died from
TABLE 2 Baseline Characteristics
Survived Died p Value
Demographics
Age, yrs 32  17 39  31 0.16
Male 486/1,015 (48) 20/24 (83) 0.001
Weight, kg 77.5  21.4 91.0  35.1 0.075
Height, cm 168  11 164  12 0.23
Body mass index 27.1  6.6 32.3  10.4 0.016
Black* 66/771 (8.6) 2/13 (15.4) 0.39
Hispanic* 99/726 (14) 3/13 (23) 0.33
Smoking/vaping 80/1,020 (7.8) 1/24 (4.2) 0.51
Medications
ACE/ARB use 274/1,005 (27) 9/24 (38) 0.27
Beta-blocker use 348/1,007 (34) 12/24 (50) 0.65
Medical/cardiac history
Previous atrial arrhythmia 248/1,002 (25) 11/24 (46) 0.019
Pacemaker or implanted defibrillator 103/1,009 (12.9) 2/24 (8.3) 0.66
Hypertension 156/1,003 (16) 5/24 (21) 0.48
Diabetes 58/1,014 (5.7) 7/24 (29.2) <0.001
Known coronary artery disease 22/1,004 (2.2) 2/24 (8.3) 0.049
Previous heart failure admission 88/1,001 (8.8) 10/24 (42) <0.001
Ejection fraction <40% 34/654 (5.2) 1/19 (5.3) 0.99
Systemic ventricular ejection fraction by echo 57  10 54  9 0.19
Systemic right ventricle (biventricular) 59/1,020 (5.8) 2/4 (50) 0.60
Moderate-severe valve dysfunction 333/807 (41) 13/20 (65) 0.058
Fontan palliation 115/1,017 (11.3) 3/24 (12.5) 0.86
Pulmonary hypertension 66/1,008 (6.5) 7/24 (29) <0.001
Sub-pulmonic ventricular systolic
pressure by echo, mm Hg
39  22 54  30 0.006
Previous resting oxygen saturation, % 96  4 92  5 <0.001
Cyanosis (oxygen saturation <90%) 74/998 (7.7) 10/24 (42) <0.001
Supplemental oxygen use 28/1,002 (2.8) 4/24 (17) <0.001
Laboratory findings
Hemoglobin 14.2  3.1 15.5  3.4 0.09
Creatinine, mg/dl 0.87  0.35 1.29  1.19 0.086
eGFR <60 ml/min/1.73 m2† 38/1,015 (3.7) 4/24 (17) 0.001
Albumin, mg/dl 4.3  0.6 4.0  0.7 0.042
Values are mean  SD or n/N (%). *Data on race and ethnicity were requested from U.S. centers. †Estimated
glomerular filtration rate (eGFR) is based on the Modification of Diet in Renal Disease equation.
ACE ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker medication.
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1649metastatic cancer, 1 from bacterial pneumonia, and 1
from cardiac arrest at home without previous positive
COVID-19 testing. One additional death occurred in a
patient with a systemic right ventricle who, 4 months
after COVID-19 hospitalization, presented with ven-
tricular arrhythmia and cardiogenic shock. The
remaining 24 deaths (mean age: 40.8  17.6 years;
range 18 to 85 years; 75% male) were all adjudicated
as COVID-19 related, resulting in a 2.3% COVID-19
related case/fatality rate (95% CI: 1.4% to 3.2%). All
were PCR positive, except 1 young adult with an un-
corrected atrioventricular septal defect and Eisen-
menger syndrome who presented with fever, cough,
anosmia, myalgia, and an elevated leukocyte count,
and who died of hemoptysis. Treating providers
deemed the clinical picture consistent with COVID-19,
although testing could not be performed. When
analysis was restricted to the 907 patients with posi-
tive PCR or antibodies, the COVID-19 case/fatality
ratio was 2.5% (95% CI: 1.5% to 3.6%).
All COVID-19 deaths occurred in hospitalized sub-
jects. Median hospital duration before death was
9 days (range 1 to 74 days). Of these, 19 patients were
intubated, 10 had a significantly elevated troponin
consistent with myocardial damage, 9 required renal
replacement therapy, and 3 were placed on extra-
corporeal membrane oxygenation. One patient had
been living in a nursing home before infection and
had previously decided against resuscitation. In
terms of CHD diagnoses, 10 patients were cyanotic, 5
of whom had Eisenmenger syndrome. Two additional
patients had pulmonary arterial hypertension (PAH)
without cyanosis. Three patients who died had Fon-
tan physiology. One had asplenia, poor systolic
function, and protein-losing enteropathy and pre-
sented in respiratory distress; the second had ‘failing
Fontan’ physiology with multiple admissions prior to
infection; the third had resting cyanosis, prior atrial
and ventricular arrhythmia, and mitral valve
dysfunction. Two patients had a systemic RV in the
setting of transposition of the great arteries, both of
whom had had multiple prior admissions for
congestive heart failure. There were 7 deaths in pa-
tients with diabetes, all obese, age 42 to 85 years, and
all with simple defects.
RISK FACTORS FOR DEATH. Factors associated with
death (Table 2) included male sex, higher body mass
index, previous atrial arrhythmia, diabetes, previous
heart failure admission, cyanosis, lower resting oxy-
gen saturation, PAH, increased subpulmonic ventric-
ular systolic pressure as estimated by the most recent
echocardiogram, and eGFR <60 ml/min/m2 before
infection. Age was skewed towards younger subjects(Figure 3) and was not significantly associated with
death despite a higher proportion of deaths in older
groups. Factors not associated with death were sys-
temic ventricular systolic function (either by reported
ejection fraction or semi-quantitative designation),
Fontan palliation, systemic hypertension, at least
moderate valve dysfunction, smoking and/or vaping
history, use of angiotensin-converting enzyme in-
hibitors, angiotensin receptor blockers, beta-blockers
before infection, previous arrhythmias, presence of a
pacemaker and/or defibrillator, or race/ethnicity.
Troponin elevation was also not associated with
death, because 3 of 6 patients with a normal troponin
died, and 9 of 17 patients with a troponin >50 ng/ml
survived. ORs for significant univariate predictors of
COVID-19related death are shown in Table 3.
FIGURE 3 Histogram by Age and Major Outcome
Total Severe Case Fatality
<20
61
20 - 29 30 - 39 40 - 49
158


















Columns show the study population by decade of age, with severe cases (red) and deaths (gray) indicated within each.
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and physiological stage were all strongly predictive.
Death and severe cases were distributed across the
age spectrum (Figure 3), although as a percentage
were proportionately greater in older age decades.
Anatomic complexity was not associated with death,
but physiological stage was, with a higher proportion
of deaths in more severe stages (p ¼ 0.002 by chi-
square test). Overall rates of death for stage A
(healthiest) through stage D (least healthy) were 0%,
1.1%, 3.9%, and 7.9% respectively. Paradoxically,
there were no deaths among the complex anatomy þ
physiological stage D group (n ¼ 0 of 16); rather, the
highest rates of death were among those with simple
anatomy þ physiological stage D (n ¼ 3 of 19).
To further consider the possible effects of age on
anatomic and physiological designations, we dividedthe entire cohort into age tertiles, specifically 18 to 27
years, 28 to 39 years, and 40 years or older (Table 4).
Deaths were more common in the oldest tertile
(3.8%). In each tertile, deaths were generally more
common in physiological stage C or D, regardless of
anatomic complexity. To explore the potential for
interaction between anatomy and physiology as pre-
dictors of death, we performed a multiple binary lo-
gistic regression analysis using physiological stages
(AB vs. CD) and anatomic complexity (severe vs.
simple and/or moderate) as independent variables.
Physiological stage CD was predictive (OR: 6.6;
95% CI: 2.2 to 19.4; p ¼ 0.001), whereas complex
anatomy was not predictive (OR: 0.7; 95% CI: 0.3 to
1.9; p ¼ 0.47).
Rates of mortality and/or severe course varied by
CHD diagnosis (Central Illustration). The highest
CENTRAL ILLUSTRATION Major Outcome by Defect Type
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Age (Mean ± SD)
Total Cohort (N = 1,044)
Conotruncal Abnormalities (N = 197)
Fontan Physiology* (N = 118)
Anomalous Coronary Arteries (N = 24)
Pulmonary Valve/Artery Stenosis (N = 60)
Anomalous Pulmonary Venous Return (N = 35)
Simple Shunt (N = 118)
Mitral Valve Defect (N = 20)
Bicuspid/Unicuspid Aortic Valve (N = 127)
Coarctation and Variants (N = 81)
Ebstein Anomaly (N = 31)
Subaortic Stenosis (N = 30)
TGA Arterial Switch (N = 39)
Pulmonary Atresia with Intact Septum (N = 15)
Single Ventricle (RV Morphology) (N = 27)
Double Outlet RV (N = 20)
Familial Aortopathy (Marfans, etc) (N = 16)
Eisenmenger Physiology (N = 24)
Cyanosis (SaO2 <90%)* (N = 84)
Pulmonary Arterial Hypertension* (N = 73)
Congenitally Corrected TGA (N = 25)
TGA Atrial Switch (N = 33)
Single Ventricle (LV Morphology) (N = 89)
Atrioventricular Septal Defect (N = 32)











































































Fatality Severe Case Mild Case
Broberg, C.S. et al. J Am Coll Cardiol. 2021;77(13):1644–55.
Breakdown of the entire cohort by congenital defect category. Those with severe disease exclusive of death (red) and fatal cases (gray) are indicated, with
percentage by category. *Groups that were not exclusive of others; patients with cyanosis, pulmonary hypertension, or Fontan are pooled regardless of
underlying anatomy. All other groups are mutually exclusive. Age distribution is given for each category. Conotruncal abnormalities include tetralogy
of Fallot, pulmonary atresia with ventricular septal defect, and truncus arteriosus. LV ¼ left ventricle; RV¼ right ventricle; TGA ¼ transposition of
the great arteries.
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1651mortality rates were observed in patients with
Eisenmenger physiology, patients with cyanosis (with
or without PAH), and those with PAH (with or without
cyanosis). Of patients with cyanosis but without PAH,
there were 5 deaths among 47 (10.6%). Conversely, of
35 patients with PAH but without cyanosis, only 2
died (5.7%). Generally, defect groups with higher
mortality tended to have an older mean age (Central
Illustration).
All analyses were repeated using only the cohort of
907 patients who tested positive by PCR or who had
confirmed positive antibody testing after a clinical
presentation. There were no changes in variablesignificance; male sex, oxygen saturation, use of
supplemental oxygen, cyanosis, PAH, previous heart
failure admission, diabetes, physiological stage,
creatinine, low eGFR, and estimated sub-pulmonic
ventricular systolic pressure remained significant.
However, beta-blocker use and lower left ventricular
ejection fraction were significantly associated with
COVID-19related death. Other variables were not.
SECONDARY OUTCOME: SEVERE CASES. There were
67 (6.4%) patients who required ICU care, 36 of whom
were intubated. Of those intubated, 18 (52%) died.
Variables of significance for predicting severe disease
course (Table 5) were identical to those predictive of
TABLE 3 ORs for Variables Associated With Case/Fatality
OR 95% CI p Value
Cyanosis (oxygen saturation <90%) 8.9 3.820.8 <0.001
Previous heart failure admission 7.4 3.2–17.2 <0.001
Diabetes 6.8 2.7–17.0 <0.001
Physiological stage C or D 6.4 2.2–19.0 0.001
Supplemental oxygen use 7.0 2.2–21.7 0.001
Pulmonary arterial hypertension 5.9 2.4–14.7 <0.001
Male 5.4 1.816.0 0.002
eGFR <60 ml/min/1.73 m2 5.1 1.715.8 0.004
Body mass index 1.08 1.041.13 0.001
Age (per yr) 1.03 1.0021.06 0.033
CI ¼ confidence interval; OR ¼ odds ratio; other abbreviation as in Table 2.























Values are n/N (%). Colum
Groups with $3% fatality
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1652death. Beta-blockers and having a systemic right
ventricle were also significant. Additional complica-
tions from the entire cohort included new arrhyth-
mias in 36 (3.4%) patients and bleeding or
coagulopathic events (as judged by contributing
providers) in 32 (3.1%) patients. Of the 23 pregnant
women, all survived, but 2 were treated in the ICU
late in pregnancy.
DISCUSSION
In adults with CHD, we found a case/fatality ratio
from COVID-19 of 2.3% (95% CI: 1.4% to 3.2%) among
mostly symptomatic infections. This figure wasased on Anatomic Complexity or Physiological Stage (by
age A Stage B Stage C Stage D Total
27 (0) 0/29 (0) 1/32 (3.1) 1/6 (16.7) 2/94 (2.1)
36 (0) 1/73 (1.4) 1/38 (2.6) 1/6 (16.7) 3/153 (2)
24 (0) 0/34 (0) 2/45 (4.4) 0/6 (0) 2/109 (1.8)
87 (0) 1/136 (0.7) 4/115 (3.5) 2/18 (11.1) 7/356 (2)
21 (0) 0/32 (0) 0/32 (0) 0/5 (0) 0/90 (0)
26 (0) 1/57 (1.8) 2/74 (2.7) 0/11 (0) 3/168 (1.8)
17 (0) 0/33 (0) 2/48 (4.2) 0/4 (0) 2/102 (2)
64 (0) 1/122 (0.8) 4/154 (2.6) 0/20 (0) 5/360 (1.4)
22 (0) 0/26 (0) 2/35 (5.7) 2/8 (25) 4/91 (4.4)
26 (0) 1/62 (1.6) 5/71 (7) 1/11 (9.1) 7/170 (4.1)
3 (0) 1/21 (4.8) 0/21 (0) 0/6 (0) 1/51 (2)
51 (0) 2/109 (1.8) 7/127 (5.5) 3/25 (12) 12/312 (3.8)
70 (0) 0/87 (0) 3/99 (3) 3/19 (15.8) 6/275 (2.2)
88 (0) 3/192 (1.6) 8/183 (4.4) 2/28 (7.1) 13/491 (2.6)
44 (0) 1/88 (1.1) 4/114 (3.5) 0/16 (0) 5/262 (1.9)
02 (0) 4/367 (1.1) 15/396 (3.8) 5/63 (7.9) 24/1028 (2.3)
ns represent different physiological stages. Anatomic complexity is given by row.
rate are indicated in bold.harmonious with the reported cumulative world fa-
tality rate of 2.2%, although mortality varied consid-
erably by location (14). Early experience with the
COVID-19 pandemic identified heart disease as a risk
factor but likely implied heart failure, coronary
atherosclerosis, cardiomyopathies, and PAH (15). Our
data suggested that extrapolation to include adults
with CHD could be problematic, because many did
not have these acquired cardiovascular problems or
other high-risk features. Yet, our findings confirmed
noncardiac risk factors reported elsewhere, including
obesity, diabetes, and pregnancy (16,17).
Older age was a risk factor for COVID-related death
in the general population. Our population was
skewed towards younger ages, which might have
affected some comparisons. The case/fatality ratio
tended to be higher in the older age tertile, and age
was a univariate predictor by binary regression. Many
patients with CHD were younger, particularly pa-
tients with a Fontan single ventricle, which might
offer protection and explain some of the favorable
outcomes in our study. In addition, the anatomic
and/or physiological makeup of the population with
CHD population was expected to differ by age, with
more complex anatomy expected in younger groups
but more complex physiology in older groups. Thus,
it was plausible that elements defining stage C or D in
younger individuals differed from older patients,
regardless of physiological status as determined by
factors such as PAH, heart failure, or cyanosis, which
clearly affected outcome.
Anatomic complexity in the absence of advanced
physiological status did not seem to increase risk,
consistent with published experience (8,18). For
example, a patient with noncyanotic Fontan physi-
ology without heart failure or arrhythmia did not
appear to be at higher risk for COVID-19 death or se-
vere infection compared with someone without CHD
with comparable comorbidities, although many CHD
providers might have predicted otherwise. However,
there was inherent heterogeneity within the CHD
spectrum, which encompassed a range of anatomic
and physiological states, and some patients did fall
into high-risk categories.
Despite limited data, recommendations based on
sensible assumptions from what is known about the
CHD community of patients have been published
(10,11). Only 2 previous publications addressed
COVID-19 in the CHD population from areas with high
early incidence. The first, from Italy, reported that
clinical event rates were not high, and there were no
deaths. However, most patients had clinically sus-
pected virus rather than confirmed infection by PCR
(7). In the second, a recent a study of 53 PCR-positive
TABLE 5 Factors Compared Based on Mild Versus Severe Cases
Mild Case Severe Case* p Value
Demographics
Age, yrs 32  16 40  23 0.001
Male 454/963 (47) 52/76 (68) <0.001
Weight, kg 77.5  20.8 83.0  33.0 0.16
Height, cm 168  11 166  12 0.063
Body mass index 27.2  6.5 29.2 9.9 0.091
Smoking/vaping history 76/967 (7.9) 5/77 (6.5) 0.66
Black 62/739 (8.4) 6/45 (13.3) 0.25
Hispanic 93/695 (14) 9/44 (21) 0.19
Medications
ACE/ARB use 255/953 (27) 28/76 (37) 0.058
Beta-blocker use 325/956 (34) 35/75 (46) 0.027
Medical/cardiac history
Previous atrial arrhythmia 233/950 (25) 26/76 (34) 0.061
Pacemaker or implantable defibrillator 119/956 (12) 13/77 (17) 0.26
Hypertension 147/951 (16) 14/76 (18) 0.49
Diabetes 50/961 (5.2) 15/77 (20) <0.001
Known coronary artery disease 20/952 (2.1) 4/76 (5.3) 0.079
Previous heart failure admission 72/951 (7.6) 26/74 (35) <0.001
Ejection fraction <40% 29/617 (4.7) 6/56 (11) 0.052
Systemic ventricular ejection fraction by echo 57  10 53  10 0.001
Systemic right ventricle (biventricular) 51/967 (5.3) 10/77 (13) 0.005
Moderate-severe valve dysfunction by echo 316/766 (41) 30/61 (49) 0.28
Fontan palliation 108/964 (11.2) 10/77 (13) 0.64
Pulmonary hypertension 58/955 (6.1) 15/77 (20) <0.001
Sub-pulmonic ventricular systolic
pressure by echo, mm Hg
38  21 52  28 0.006
Previous resting oxygen saturation, % 96  4 93  6 <0.001
Cyanosis (oxygen saturation <90%) 64/947 (6.8) 20/75 (27) <0.001
Supplemental oxygen use 24/950 (2.5) 8/76 (10.5) <0.001
Laboratory findings
Hemoglobin 14.21  3.1 14.8 2.8 0.105
Creatinine, mg/dl 0.86  0.34 1.12  0.85 0.043
eGFR <60 ml/min/1.73 m2 35/962 (3.6) 7/77 (9.1) 0.019
Albumin, mg/dl 4.3  0.6 4.0  0.6 0.013
Values are mean  SD or n/N (%). *Severe case includes need for intensive care, endotracheal intubation, renal
replacement therapy, extracorporeal membrane oxygenation, or death.
Abbreviations as in Table 2.
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1653subjects with CHD who received care in New York
City, there were 3 (6%) deaths (8). Those at highest
risk of death or severe infections were adults with
advanced physiological stages (C and D) (9). The
present study, which was approximately 20-fold
higher than these previous publications, showed a
case/fatality ratio similar to that of the general pop-
ulation (19).
Concern for myocardial damage from these and
other viruses is inherently justifiable.
Historical data from previous viral epidemics
confirmed adverse pulmonary and cardiovascular ef-
fects in the patient population with CHD (20–22).
Cardiac injury from these challenges might have
resulted from an overwhelming immune inflamma-
tory cytokine response, direct viral invasion of car-
diomyocytes, or poor myocardial oxygenation from
severe hypoxia due to lung injury (23). These mech-
anisms might have plausibly complicated patients
with CHD who were already prone to myocardial
dysfunction, limited myocardial oxygenation, or
pulmonary vascular disease. Yet. it could also be
postulated that pre-conditioning in CHD paradoxi-
cally protects the myocardium to such stresses, and
thus lessens the overall impact on the myocardium
(12). We found little risk from systolic dysfunction or
valve dysfunction, although our assessments of these
were subjective and not uniformly assessed among
centers. However, we did find significant risk in those
with previous heart failure admission, which was
consistent with other reports of CHD and PAH (24,25).
Our data confirmed that cyanosis and PAH, espe-
cially when combined (Eisenmenger syndrome),
portends a high rate of adverse events. This was not
surprising because of the reduced functional capac-
ity, multiorgan consequences of chronic cyanosis and
the limited reserve of these patients (26–29).
Increased risk from COVID-19 in PAH was docu-
mented (30). It was less clear whether cyanosis or
PAH conveyed the most vulnerability; our limited
experience suggested that cyanosis might be the
stronger risk factor. We found that 6% of patients
with CHD required ICU admission, a lower rate than
that observed in non-CHD hospitalized patients (31).
The spectrum of presenting symptoms of COVID-19
in our population was similar to those described in
the general population, although fever was less
frequent (44% vs. 90%) (32). Reasons for this
discrepancy are not clear but likely reflect less
vigorous reporting methods herein. Of note, 6% of
patients were completely asymptomatic; diagnoses
were made incidentally through COVID PCR testing
before a procedure or after a known exposure. The
increasing availability and access to PCR andserological testing as the months of the pandemic
unfolded allowed for inclusion of mostly confirmed
positive COVID-19 cases in our study compared with
previous publications (7). However, the denominator
in any case/fatality ratio remains fluid because it is
dependent on multiple physiological, institutional,
psychosocial, and even geopolitical factors.
STUDY LIMITATIONS. Our study could not determine
the rate of infection among adults with CHD, because
it was impossible to accurately measure the size of
the population from which to base our case load. All
patients in our study were followed by CHD centers,
meaning the study was susceptible to referral bias
and could thus have included more complicated pa-
tients with CHD and/or worse COVID-19 infections.
PERSPECTIVES
COMPETENCY IN PATIENT CARE: The case/fa-
tality rate among adults with CHD who develop novel
coronavirus infection is 2.3%. Mortality is more
closely related to physiological factors such as
cyanosis and pulmonary hypertension and to male
sex, diabetes, and renal insufficiency, than to the
complexity of cardiac defects.
TRANSLATIONAL OUTLOOK: Systematic efforts
are needed to target preventive measures at patients
with CHD who are at greatest risk of mortality and
severe morbidity due to COVID-19.
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were infected but did not have access to specialized
CHD care could not be determined. We included 60
asymptomatic patients; this implied there were likely
other asymptomatic carriers among the population,
although the prevalence of asymptomatic infections
was unknown. The preceding limitations suggested
that the true case/fatality ratio might actually be
lower. It could be argued also that our sample
included those with better access to care, and there-
fore, they had better outcomes than others not
accounted for herein. In addition, we had predomi-
nantly American participation with lower participa-
tion from adult CHD centers with different
socioeconomics and health care delivery models and
could not confidently generalize our findings to pa-
tients globally.
Because we identified 24 COVID-19 related deaths,
risk factor analysis was limited, and potential effects
of confounding were more difficult to explore. Spe-
cifically, multivariate regression or risk score
modeling was limited to study-only specific potential
confounding. Due to referral bias, our sample might
have had over-representation of sicker or more com-
plex patients, including asymptomatic patients with
who had PCR testing before procedures. This might
partly explain our paradoxical finding of a slightly
lower mortality among those with complex lesions
(Table 4). A recent change in case complexity among
inpatient CHD services during the pandemic was
shown (33).
Our study focused on short-term death and serious
complications and did not address potential medium-
and long-term complications. Our identification of
severe cases might facilitate future study of unfa-
vorable physiological downstream effects. There
were also known neuropsychiatric outcomes (33) and
emerging information about longer-term conse-
quences of patients hospitalized for COVID-19 (34,35).
Although we did not observe a relationship be-
tween our primary or secondary outcomes with race/
ethnicity among the U.S. cohort, this should not be
interpreted to suggest that Black and Hispanic adults
with CHD were not disproportionately affected by
COVID-19. Authors of a recent systematic review of 37
studies reported that African American/Black and
Hispanic populations had higher rates of infection,
hospitalization, and COVID-19related deaths
compared with non-Hispanic White populations,
although case/fatality rates did not differ (36). It was
likely that factors related to health care access,
exposure (36), and racism (37) would also affectoutcomes of Black and Hispanic adults with CHD
living in the United States.
CONCLUSIONS
We found that the presence of a structural congenital
heart defect did not necessarily portend an increased
risk of mortality or morbidity from COVID-19 infec-
tion. This finding was important for both patients and
providers worldwide who are now facing high
numbers of cases throughout the population. Yet,
recognizing the inherent heterogeneity across the
CHD population, we identified several factors asso-
ciated with mortality and severe infections. These
showed that susceptibility might be based on physi-
ological factors, not the complexity of the underlying
anatomic defect. Our findings were harmonious with
general population studies that showed risks associ-
ated with age, male sex, diabetes, and renal
insufficiency.
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